Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.
about
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicityExercise Prevention of Cardiovascular Disease in Breast Cancer SurvivorsPotential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer DrugsChemotherapy-Induced Cardiotoxicity: Pathophysiology and PreventionMolecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up.Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer PatientsTwisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage.N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes -- involvement of uncoupling protein UCP2.Cardiovascular toxicities from systemic breast cancer therapy.Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.Interlinked DNA nano-circles for measuring topoisomerase II activity at the level of single decatenation events.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.The regulatory mechanisms of myogenin expression in doxorubicin-treated rat cardiomyocytesThe dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religationMechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.Cardiotoxicity of anthracycline therapy: current perspectivesTargeting of topoisomerases for prognosis and drug resistance in ovarian cancer.A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Anthocyanin Attenuates Doxorubicin-Induced Cardiomyotoxicity via Estrogen Receptor-α/β and Stabilizes HSF1 to Inhibit the IGF-IIR Apoptotic Pathway.Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.Mitoxantrone, More than Just Another Topoisomerase II Poison.Systems biology approaches to adverse drug effects: the example of cardio-oncology.Cardio-oncology: cardiovascular complications of cancer therapy.Natural variation in a single amino acid substitution underlies physiological responses to topoisomerase II poisons.Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond.Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors.Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.The influence of chemotherapy on the right ventricle: did we forget something?Cancer as a Risk Factor for Cardiovascular Disease.Chemotherapy-induced cardiotoxicity in children.Genes required for survival in microgravity revealed by genome-wide yeast deletion collections cultured during spaceflight.A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin.Subclinical ventricular dysfunction detected by speckle-tracking two years after use of anthracycline.Naphthoquinones: A continuing source for discovery of therapeutic antineoplastic agents.The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.
P2860
Q26744675-F339AB6A-8987-4300-B175-78F89C9323ECQ26785410-9A142C03-56B0-4B6F-8EB4-E6C8A2387AD1Q28070311-5FA6228B-211D-4733-B8E5-C3F4FE8398F8Q30399577-C480D14A-F7CD-460E-B3B1-3F7E5A04DAA5Q33578496-44620D3B-5DAB-462A-8E1E-D78C343E8A39Q33816471-CA66546C-E592-43B3-827C-DC49081B40ACQ34375948-EDFA095E-6E71-48DE-9748-124F9FFC3944Q34544057-71118D78-AFAE-44FF-8BBF-E14468318F60Q34630349-FCD9E7DA-388E-46F1-AC1E-79488099F33AQ35550223-2601B9A3-F4E0-43CC-B44B-DA29F04B0D91Q36379849-C77CF744-52FF-403D-9C67-F31F90281E21Q36451899-FD25CE4F-29DF-49DB-89A1-7C4B6121BC75Q36545773-CA08F806-B90B-4CE1-BEB0-DAC8F1BA0102Q36545904-9F143883-99C8-4919-8317-D1F3E5DE804DQ36559677-E24D418C-E443-4773-822E-937C4FF83B15Q36845348-2F6B8C57-2AE2-4541-B8D9-6804886AFC38Q37018096-7A092FAA-96D3-43DE-AD85-57CB164B3FBFQ37204002-B232C5AD-E62E-4DFA-8CB7-78D61030D9AAQ37286660-4F94510D-64B8-4A10-AE61-2E9D5EF2C000Q37311943-DBEB0DE5-6750-49E3-8BC6-7B00C7E947E7Q38569206-C50EFF69-DC4C-47D8-B3E9-BC428F3CE3A9Q38606067-A3A8BE2F-68D2-4150-B7B6-89E2B57DA15CQ38665281-61346407-F945-4828-97EC-102FE9AB3C7FQ38682376-D1AF856B-E3C7-4900-9DE0-2F0C6E222B4DQ38800300-5CCADF7E-E59E-477C-8ECC-F8CC487EE5DDQ38876257-DD2AE14A-C631-49B2-9F94-6CA921323D0EQ38978030-E475AC38-1E82-4A1E-9AF8-622F71584D57Q39010412-F11A28AD-8E54-483B-8C91-9CEB71FEEBB9Q39012650-644191B4-A668-42F9-8F6C-860C608B7464Q39133246-FBACA132-CE3C-45F0-97BD-F38828A955BCQ39249961-5351F49A-11B4-4A9D-BE70-1ADD645705E7Q39415815-D520D299-8EAB-4052-B242-63BBE43E952AQ41455313-543435E2-B56D-4766-94FB-933654D0276DQ41881917-73D16076-C006-404D-8C3F-713CC6160637Q43077330-66D9EBAC-4A62-46E1-9718-5E376C0FE259Q46262914-55C23088-AE49-4409-BD6F-75A18FD52A5CQ46269647-053B8CDD-EC25-4634-9950-A73BA82E29B5Q48170012-19F60B68-A63A-4538-B4E4-B12DB0A7C822
P2860
Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Topoisomerase 2β: a promising ...... ycline-induced cardiotoxicity.
@en
type
label
Topoisomerase 2β: a promising ...... ycline-induced cardiotoxicity.
@en
prefLabel
Topoisomerase 2β: a promising ...... ycline-induced cardiotoxicity.
@en
P2860
P356
P1476
Topoisomerase 2β: a promising ...... ycline-induced cardiotoxicity.
@en
P2093
P Vejpongsa
P2860
P356
10.1038/CLPT.2013.201
P407
P577
2013-10-03T00:00:00Z